Back to top

Analyst Blog

Dynavax Technologies Corporation (DVAX - Snapshot Report) posted a loss of 11 cents per share, wider than the Zacks Consensus Estimate of a loss of 8 cents per share and the year-ago loss of 3 cents per share.

Dynavax reported revenues of $1.8 million, down 84.2% from a year ago and much lower than the Zacks Consensus Estimate of $6 million. The huge decline was attributable to a 90% reduction in collaboration revenues to $1 million.

Collaboration revenues in the year-ago quarter were higher due to the recognition of certain milestones achieved as per Dynavax's partnership with GlaxoSmithKline (GSK - Analyst Report) to develop and commercialize toll-like receptor (TLR) inhibitors.

Research and development expenses increased 7.7% year over year to $12.5 million.

General and administrative expenses jumped 104.4% year over year to $9.3 million due to higher stock-based compensation expenses, an increase in administrative headcount and market research costs related to hepatitis B vaccine, Heplisav.

Dynavax is developing Heplisav, in collaboration with GlaxoSmithKline.

We note that Heplisav is under review in Europe. In Feb 2013, the company received a setback in its efforts to get the candidate approved in the US.

The US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the company refusing to approve Heplisav in adults in age bracket 18-70 without further evaluation of safety. The company intends to meet the FDA shortly to discuss the steps necessary to get the candidate approved.

Apart from lead candidate Heplisav, Dynavax is also developing another candidate. We remind investors that Dynavax is developing AZD1419, a proprietary second generation TLR-9 for the treatment of asthma, in partnership with AstraZeneca (AZN - Analyst Report). 

Total revenues in 2012 were $9.7 million, down 55.0% year over year and significantly below the Zacks Consensus Estimate of $14 million. Loss per share of 41 cents was wider than the loss of 39 cents posted in 2011 and the Zacks Consensus Estimate of 37 cents.

Dynavax carries a Zacks Rank #3 (Hold). Right now, Array Biopharma (ARRY - Snapshot Report) looks well placed in the pharma sector with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%